Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus Rhamnosus GG and Inflammation: Effects on Markers Like LPS

This conversation explores the evidence on Lactobacillus rhamnosus GG's impact on inflammation markers, including general cytokines (TNF-α, IL-6, IL-10) and specific lipopolysaccharide (LPS) levels. Findings show promising benefits for systemic inflammation but neutral results for LPS reduction based on Pillser's research database.

  • Does taking Lactobacillus rhamnosus GG help reduce inflammation markers like lipopolysaccharide in the body?

  • Based on Pillser's research database, here's what the evidence shows:

    General Inflammation Markers

    There is promising evidence that Lactobacillus rhamnosus GG can help reduce certain markers of inflammation. Pillser's database contains 2 studies on this topic, both showing beneficial effects1:

    1. A 2026 narrative review found that L. rhamnosus GG can "attenuate inflammation through cytokine modulation" — specifically by increasing anti-inflammatory IL-10 and decreasing pro-inflammatory TNF-α and IL-62.

    2. A 2025 observational study on diabetic kidney disease prevention reported that pro-inflammatory cytokines (IL-6, TNF-α) decreased significantly, while anti-inflammatory mediators (IL-10, TGF-β) showed enhanced expression3.

    Lipopolysaccharide (LPS) Specifically

    When it comes to lipopolysaccharide levels, the picture is less clear. Pillser has 1 clinical trial on this specific outcome, which showed a neutral result4:

    • A 2018 clinical trial (n=45) in HIV-infected individuals, using a dose of 6 × 10⁹ CFU twice daily, found no significant changes in lipopolysaccharide levels or other markers of microbial translocation (such as sCD14, sCD163, and high-sensitivity CRP)5.

    Summary

    OutcomeStudiesFindings
    General inflammation (TNF-α, IL-6, IL-10)2 studies, both beneficialEvidence suggests L. rhamnosus GG can modulate cytokines in a favorable direction
    Lipopolysaccharide (LPS) levels1 study, neutralNo significant reduction was observed in the single clinical trial

    In short, Lactobacillus rhamnosus GG appears to help with systemic inflammatory markers like TNF-α and IL-6, but the evidence does not currently support its use specifically for reducing lipopolysaccharide levels in the blood. More research is needed on the LPS front.

    Footnotes

    1. Pillser research database, Lactobacillus rhamnosus GG and Reduced Inflammation ↩

    2. "Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review" (2026), Pillser ↩

    3. "Gut Microbiome Engineering for Diabetic Kidney Disease Prevention: A Lactobacillus rhamnosus GG Intervention Study" (2025), Pillser ↩

    4. Pillser research database, Lactobacillus rhamnosus GG and Reduced Lipopolysaccharide Level ↩

    5. "Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals" (2018), Pillser ↩

New Topic

Browse Related Questions

Back to top